1. Home
  2. TOVX

TOVX

Theriva Biologics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 2:32pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Founded: 2001 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 8.4M IPO Year: 2006
Target Price: N/A AVG Volume (30 days): 98.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.14 EPS Growth: N/A
52 Week Low/High: $0.20 - $1.20 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: